Related Experiment Video
Updated: Oct 11, 2025
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
4.8K
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.
Sua Lee1, Shina Jang1, Jihoon Kang1
1Department of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.
Frontiers in Immunology
|December 6, 2021
Summary
A new humanized monoclonal antibody, MG1141A, effectively neutralizes SARS-CoV-2, including key variants. This antibody offers a promising therapeutic approach against emerging mutations of the virus.
Area of Science:
- Immunology
- Virology
- Biotechnology
Background:
- Antibody therapeutics are crucial for treating SARS-CoV-2 infections.
- Mutations in the SARS-CoV-2 spike protein can reduce the efficacy of existing antibody treatments.
- There is a need for broadly neutralizing antibodies effective against viral variants.
Purpose of the Study:
- To develop a universal neutralizing antibody against SARS-CoV-2.
- To investigate the efficacy of a novel humanized monoclonal antibody, MG1141A, against SARS-CoV-2 and its variants.
Main Methods:
- Generation of a humanized monoclonal antibody (MG1141A) targeting the spike protein's receptor-binding domain via mouse immunization.
- Assessment of live virus neutralization activity and Fc-mediated functions.
- Evaluation of neutralizing activity against SARS-CoV-2 variants (Alpha, Beta, Gamma).
Main Results:
- MG1141A demonstrated potent neutralization of live SARS-CoV-2 with an EC50 of 92 pM.
- The antibody exhibited effective Fc-mediated functions.
- MG1141A retained neutralizing activity against Alpha, Beta, and Gamma SARS-CoV-2 variants.
Conclusions:
- MG1141A is a potent neutralizing antibody effective against SARS-CoV-2 and its variants.
- This novel antibody represents a potential therapeutic strategy to overcome challenges posed by emerging viral mutations.
- The study contributes to the development of next-generation antibody therapies for coronaviruses.
